About Zyl Therapeutics
Zyl Therapeutics is a Technology company based in Greenville (United States) founded in 2017 by Scott Pancoast. Hydrogel-derived nanoparticles for topical drug delivery are developed. It operates in the Technology and Healthcare sectors. Zyl Therapeutics has raised $9.43 million across 6 funding rounds from investors including NIH, SCRA and NIH SBIR/STTR. Its chief executive, as recorded, is Scott Pancoast. Zyl Therapeutics offers products and services including Z-pods. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science. Its competitors include PanTher Therapeutics, Sirnaomics and Ensysce; 3 of its 3 listed competitors have raised funding.
Company details
Zyl Therapeutics was founded in 2017 and is based in Greenville, United States. A patented drug delivery system known as Nanopods, derived from hydrogels, is developed by the company for topical applications. Payloads including nitric oxide, curcumin, cannabis, siRNA, iron, and melanin can be delivered through this system. Operations focus on biotechnology and pharmaceutical sectors, with emphasis on nanoparticle innovations for skin-based treatments.
- Headquarters Greenville, United States
- Founders Scott Pancoast
- SectorsTechnologyHealthcare
- Email••••••••
- Phone•••• ••••
- Website zylotherapeutics.com
- Social LinkedIn Facebook
- Total Equity Funding$9.43M (USD)
in 6 rounds
- Latest Funding Round$294K (USD), Grant
May 2023
- InvestorsNIH
& 9 more
Products & Services of Zyl Therapeutics
Zyl Therapeutics offers a comprehensive portfolio of products and services, including Z-pods.
Technology for innovative and sustained topical drug delivery.
Funding Insights of Zyl Therapeutics
Zyl Therapeutics has successfully raised a total of $9.43M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $294 thousand completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.43M
- Total Rounds 6
- Last Round Grant — $294,000
- First Round $1.35M
(Jun 2018)
- Investors Count 10
All 6 funding rounds of Zyl Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $294,000 | Grant | – | – | |
| Sep 2022 | $263,000 | Grant | – | – | |
| Jun 2022 | $5.23M | Series B | – | VentureSouth, New York Angels | – |
| Sep 2019 | $2.65M | Series A | – | VentureSouth | |
| Jun 2019 | $200,000 | Series A | – | VentureSouth | – |
| Jun 2018 | $1.35M | Series A | – | – | – |
10 investors in total: 10 institutional.
Investors in Zyl Therapeutics
Zyl Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, SCRA and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sbir.nih.gov | ||||
Early-stage ventures in the Southeast are supported by VentureSouth. | 2014 | venturesouth.vc | Greenville, United States | |
Early-stage technology startups are funded by New York Angels network. | newyorkangels.com | New York, United States | ||
Startups are accelerated across sectors by SCRA. | 1983 | scra.org | United States | |
Angel investing services are provided to early-stage startups. | 2004 | bostonharborangels.com | Boston, United States | |
Cowtown Angels is recognized as Fort Worth's leading angel investor network. | cowtownangels.org | Fort Worth, United States | ||
| hbsangelsny.com | ||||
Angel investments are made in startups across various sectors. | asap-invests.com | Richmond Hill, USA | ||
| chemicalangels.com | ||||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Zyl Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zyl Therapeutics
11 people are tracked at Zyl Therapeutics (8 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Scott Pancoast | Founder & CEO | Leadership |
Scott R. Pancoast | CEO & Founder | Leadership |
Charles E Hinkle | Chief Financial Officer | Leadership |
Michael Z Rabin | VP, Strategy | Leadership |
Michael Burns | Vice President | Leadership |
Cody Reynolds | Director, Business Development | Leadership |
Andrew Draganski | Senior Director, Product Development | Leadership |
Scott Grimshaw | Director, Manufacturing & Engineering | Leadership |
Jay F. Blankenship | SVP, Business Development | Team |
Tracie Wood | Senior Manager, QA | Team |
Cam Bentley | QC Lab Manger | Team |
Complete people profiles for Zyl Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Zyl Therapeutics
3 dated milestones of Zyl Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Zyl Therapeutics is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Grant, of $294K.
Competitors of Zyl Therapeutics
Zyl Therapeutics has 3 listed competitors in our database, 3 of them funded. They include PanTher Therapeutics, Sirnaomics and Ensysce.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| panthertx.com | 2014 | Cambridge, United States | $15.35M | 47 | Drug delivery systems for inoperable solid tumors are developed. | |
| sirnaomics.com | 2007 | Gaithersburg, United States | $267M | 88 | RNA-based therapeutics for cancer and fibrosis are developed. | |
| ensysce.com | 2008 | Houston, United States | $2.5M | Drug delivery solutions via single-walled carbon nanotubes are offered. |
Detailed competitors of Zyl Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Zyl Therapeutics
The website of Zyl Therapeutics (zylotherapeutics.com) receives about 1.6K visits a month.
- Monthly visits1.6K
Top companies in Nanotechnology
3 companies that operate in the same segment as Zyl Therapeutics (Nanotechnology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 1.44 M | 29 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zyl Therapeutics
Complete news archive for Zyl Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zyl Therapeutics
Zyl Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Zyl Therapeutics is headquartered in Greenville, United States.
Scott Pancoast is the CEO of Zyl Therapeutics, as recorded in our data. They have also founded this company.
Zyl Therapeutics is a funded company, having raised a total of $9.43M across 6 funding rounds to date. The company's 1st funding round was a Series A of $1.35M, raised on Jun 2018.
Zyl Therapeutics was founded in 2017 and is based in Greenville, United States. A patented drug delivery system known as Nanopods, derived from hydrogels, is developed by the company for topical applications. Payloads including nitric oxide, curcumin, cannabis, siRNA, iron, and melanin can be delivered through this system. Operations focus on biotechnology and pharmaceutical sectors, with emphasis on nanoparticle innovations for skin-based treatments.
Zyl Therapeutics's top competitors include PanTher Therapeutics, Sirnaomics and Ensysce.
Zyl Therapeutics offers Z-pods.
Zyl Therapeutics has 10 investors. Key investors include NIH, SCRA, NIH SBIR/STTR, VentureSouth, and New York Angels.